Quintiles Acquires Targeted Molecular Diagnostics
News Dec 02, 2008
Quintiles Transnational Corp. has announced that it has acquired Targeted Molecular Diagnostics (TMD) of Westmont, Ill.
The addition of TMD to Quintiles’ Global Central Laboratories strengthens Quintiles’ service offerings in oncology, an increasingly important growth area of drug development. It provides strong capabilities in tissue-based testing, a critical component of the modern oncology drug development process.
“This acquisition is a logical addition to Quintiles’ service offerings,” said Tom Wollman, Senior Vice President, Quintiles Global Central Laboratories. “It provides us with advanced in-house pathology capabilities, including telepathology,” Wollman continued. “Most importantly, TMD’s knowledge in biomarker expression analysis adds significant new proficiencies sought by our customers.”
TMD’s biomarker technology will help Quintiles’ customers better understand how their drugs work and in which populations they’re most likely to perform best.
“With the addition of TMD’s expertise, we can help customers develop novel, targeted cancer therapies and get them to market much faster by employing biomarkers in the development process,” explained Dr. King Jolly, Senior Vice President of Drug Development Partnerships for NovaQuest, the managed partnership group of Quintiles.
“We are currently working with large pharmaceutical companies on the design of development programs. TMD will enhance our capabilities to meet those companies’ needs,” Jolly concludes.
TMD is a privately held, oncology-focused, specialty diagnostic laboratory serving the drug development process. TMD provides guidance through biomarker expression analysis and supports the development of numerous targeted therapies in oncology.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019